BiOptic Inc. is a biotechnology instrumentation company that develops innovative scientific products for research and clinical applications.
The company was founded in 2004, with a vision of establishing high-quality, value-added and customer-driven OEM/ODM solutions by developing and manufacturing products utilizing Capillary Gel Electrophoresis (CGE) Technology for biotechnology laboratories all over the world.
In 2009 BiOptic started to research and development of an innovative Capillary Gel Electrophoresis instrument utilizing disposable pen-shaped gel-cartridges. The first patented CGE-based Fragment Analyzer Qsep100TM was launched in 2011 at the Lab Automation Conference in Palm Springs, CA.
For the past 7 years, BiOptic has expanded its portfolio of products by developing and introducing several CGE instruments: the Qsep1TM, the Gly-QTM, the Qsep400TM, and most recently, the mini-PCR machine, QampminiTM, that incorporates newly launched innovative Direct-PCR reagent kits.
BiOptic strives to be the leader in the biotechnology industry by providing, easy-to-use and cost-effective CGE-based instruments and to provide innovative technical solutions for the world's top institutions, government and corporate laboratories.
With R&D, Manufacturing and Sales force located in Taiwan, and support operations in the US and China, BiOptic supports customers in over 35 Countries. Our team, over 40 years of experience in the CE industry, is recognized by our customers for our advanced instrumentation, superior customer service, scientific application support, and a very knowledgeable technical sales force. With a company-wide commitment to quality and value, we serve professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry and agriculture, performing diagnostic molecular genetic analyses.